Association between the TP53BP1 rs2602141 A/C polymorphism and cancer risk: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2917-2922

  Liu, Lei ^a   Zhang, Dong ^b   Jiao, Jing Hua ^c   Wang, Yu ^d   Wu, Jing Yang ^a   Huang, De Sheng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Fourth People's Hospital of Shenyang   (China)

^c SHENYANG MEDICAL COLLEGE   (China)

^d Department of Development and Planning Office ^*  (China)

Author keywords

Cancer; Gene; Meta analysis; Polymorphism; TP53 binding protein 1

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; NEOPLASM; PROGNOSIS; RISK FACTOR;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899832740     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2917     Document Type: Article

References (26)

1. Camargo MC, Mera R, Correa P, et al (2006). Interleukin-1 beta and interleukin-1 receptor antagonistgene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 1674-87.
2. Chen K, Hu Z, Wang LE, et al (2007). Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res, 13, 4300-5.
3. DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials, 28, 105-14.
4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
5. DiTullio RA Jr, Mochan TA, Venere M, et al (2002). P53BP 1 functions in an ATM dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol, 4, 998-1002.
6. Egger M, Davey SG, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
7. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of world wide burden of cancer in 2008: GLOBO CAN 2008. Int J Cancer, 127, 2893-917.
8. Frank B, Hemminki K, Bermejo JL, et al (2005). TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res, 7, 502-5.
9. Gao LB, Pan XM, Li LJ, et al (2011). RAD 51135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat, 125, 827-35.
10. He C, Nan H, Qureshi AA, Han J (2010). Genetic variants in the 53BP1 gene and skin cancer risk. J Invest Dermatol, 130, 2850-3.
11. Liu GY, Jiang DK, Shen SQ, Yu L (2011). MDM2 SNP309T.>G polymorphism with hepatocellular carcinoma risk: a meta-analysis. Arch Med Res, 42, 149-55.
12. Ma H, Hu Z, Zhai X, et al (2006). Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis, 27, 766-71.
13. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
14. Miwa S, Tome Y, Yano S, et al (2013). Single cell time-lapse imaging of focus formation by the DNA damage-response protein 53BP1 after UVC irradiation of human pancreatic cancer cells. Anticancer Res, 33, 1373-7.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097.
16. Naidu R, Har YC, Taib NA (2011). Genetic polymorphisms of TP53-binding protein 1 (TP53BP1) gene and association with breast cancer risk. APMIS, 119, 460-7.
17. Rappold I, Iwabuchi K, Date T, Chen J (2001). Tumor suppress or p53 binding protein1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol, 153, 613-20.
18. Rauch T, Zhong X, Pfeifer GP, Xu X (2005). 53BP1 is a Positive Regulator of the BRCA1 Promoter. Cell Cycle, 4, 1078-83.
19. Rudd MF, Webb EL, Matakidou A, et al (2006). Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res, 16, 693-701.
20. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol, 151, 1381-90.
21. Truong T, Sauter W, Mc Kay JD, et al (2010). International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-33.
22. Wang B, Matsuoka S, Carpenter PB, Elledge SJ (2002). 53BP1, a mediator of the DNA damage checkpoint. Science, 298, 1435-8.
23. Weng Y, Lu L, Yuan G, et al (2012). p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. Lei Liu et al Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 PLoS One, 7, 45820.
24. Williams RS, Green R, Glover JN (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol, 8, 838-42.
25. Zhang H, Hao S, Zhao J, et al (2013). Common Genetic Variants in 53BP1 Associated with Non-small Cell Lung Cancer Risk in Han Chinese. Arch Med Res, 45, 84-9.
26. Zhao L, Zhao X, Wu X, Tang W (2013). Association of p53 Arg72Pro polymorphism with esophageal cancer: a meta-analysis based on 14 case-control studies. Genet Test Mol Biomarkers, 17, 721-6